Tag: Leading Malaysian university starts Tocilizumab (Actemra) clinical trials for COVID-19 treatment

Leading Malaysian university starts Tocilizumab (Actemra) clinical trials for COVID-19 treatment

April 15, 2020

A present-day drug, which has been used for the treatment of rheumatoid arthritis (RA) and related, excessive inflammatory conditions, will now be evaluated by Malaysia’s Universiti Malaya Medical Centre (UMMC) as a treatment for severe cases of COVID-19. The Tocilizumab – trade name Actemra – trial is currently underway at UMMC, together with three public […]

Continue Reading